Cargando…

Protective effects of Liuweiwuling tablets on carbon tetrachloride-induced hepatic fibrosis in rats

BACKGROUND: Liuweiwuling tablets (LWWL) are an herbal product that exerts remarkable effects on liver protection and aminotransferase levels, and they have been approved by the Chinese State Food and Drug Administration (CFDA). Clinical studies have found that LWWL can inhibit collagen production an...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Huimin, Zhang, Zhenfang, Hu, Huangwanyin, Zhang, Congen, Niu, Ming, Li, Ruishen, Wang, Jiabo, Bai, Zhaofang, Xiao, Xiaohe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038198/
https://www.ncbi.nlm.nih.gov/pubmed/29986685
http://dx.doi.org/10.1186/s12906-018-2276-8
_version_ 1783338448047833088
author Liu, Huimin
Zhang, Zhenfang
Hu, Huangwanyin
Zhang, Congen
Niu, Ming
Li, Ruishen
Wang, Jiabo
Bai, Zhaofang
Xiao, Xiaohe
author_facet Liu, Huimin
Zhang, Zhenfang
Hu, Huangwanyin
Zhang, Congen
Niu, Ming
Li, Ruishen
Wang, Jiabo
Bai, Zhaofang
Xiao, Xiaohe
author_sort Liu, Huimin
collection PubMed
description BACKGROUND: Liuweiwuling tablets (LWWL) are an herbal product that exerts remarkable effects on liver protection and aminotransferase levels, and they have been approved by the Chinese State Food and Drug Administration (CFDA). Clinical studies have found that LWWL can inhibit collagen production and reduce the levels of liver fibrosis markers in the serum. Thus, LWWL is expected to have beneficial effects in the treatment of liver fibrosis. The purpose of this study was to evaluate the pharmacological effects of LWWL. METHODS: Hepatic fibrosis was induced in rats via carbon tetrachloride (CCl(4)) treatment. The rats were treated twice weekly for 8 weeks with either 2 mL·kg(− 1) body weight of a 50% solution of CCl(4) in olive oil or olive oil alone by oral gavage. A subset of rats received daily intraperitoneal injections of either colchicine (0.2 mg/kg per day), LWWL (0.4, 1.6, or 6.4 g/kg per day), or vehicle (N = 12 for all groups) during weeks 9–12. The rats were sacrificed after 12 weeks. Pathological changes in hepatic tissue were examined using hematoxylin and eosin (H&E) and Sirius Red staining. Immunohistochemistry was performed to observe α-smooth muscle actin (α-SMA) and collagen type I (collagen I) protein expression. Western blotting was also used to detect α-SMA protein expression. Real-time quantitative reverse-transcription polymerase chain reaction (RT-qPCR) was used to detect transforming growth factor-1 (TGF-β1), platelet-derived growth factor (PDGF), tissue inhibitor of metalloproteinase-1 (TIMP1), and tissue inhibitor of metalloproteinase-2 (TIMP2) mRNA expression. RESULTS: LWWL significantly reversed histological fibrosis and liver injury, reduced the hydroxyproline content in liver tissue, and decreased α-SMA and collagen I expression. LWWL also suppressed hepatic stellate cell (HSC) activation by reducing the expression of the profibrogenic factors TGF-β1 and PDGF. The expression levels of TIMP1 and TIMP2, which regulate extracellular matrix (ECM) degradation, were decreased after CCl(4) injury in LWWL-treated rats. CONCLUSIONS: These data suggest that LWWL may serve as a promising therapeutic agent to reduce fibrogenesis.
format Online
Article
Text
id pubmed-6038198
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-60381982018-07-12 Protective effects of Liuweiwuling tablets on carbon tetrachloride-induced hepatic fibrosis in rats Liu, Huimin Zhang, Zhenfang Hu, Huangwanyin Zhang, Congen Niu, Ming Li, Ruishen Wang, Jiabo Bai, Zhaofang Xiao, Xiaohe BMC Complement Altern Med Research Article BACKGROUND: Liuweiwuling tablets (LWWL) are an herbal product that exerts remarkable effects on liver protection and aminotransferase levels, and they have been approved by the Chinese State Food and Drug Administration (CFDA). Clinical studies have found that LWWL can inhibit collagen production and reduce the levels of liver fibrosis markers in the serum. Thus, LWWL is expected to have beneficial effects in the treatment of liver fibrosis. The purpose of this study was to evaluate the pharmacological effects of LWWL. METHODS: Hepatic fibrosis was induced in rats via carbon tetrachloride (CCl(4)) treatment. The rats were treated twice weekly for 8 weeks with either 2 mL·kg(− 1) body weight of a 50% solution of CCl(4) in olive oil or olive oil alone by oral gavage. A subset of rats received daily intraperitoneal injections of either colchicine (0.2 mg/kg per day), LWWL (0.4, 1.6, or 6.4 g/kg per day), or vehicle (N = 12 for all groups) during weeks 9–12. The rats were sacrificed after 12 weeks. Pathological changes in hepatic tissue were examined using hematoxylin and eosin (H&E) and Sirius Red staining. Immunohistochemistry was performed to observe α-smooth muscle actin (α-SMA) and collagen type I (collagen I) protein expression. Western blotting was also used to detect α-SMA protein expression. Real-time quantitative reverse-transcription polymerase chain reaction (RT-qPCR) was used to detect transforming growth factor-1 (TGF-β1), platelet-derived growth factor (PDGF), tissue inhibitor of metalloproteinase-1 (TIMP1), and tissue inhibitor of metalloproteinase-2 (TIMP2) mRNA expression. RESULTS: LWWL significantly reversed histological fibrosis and liver injury, reduced the hydroxyproline content in liver tissue, and decreased α-SMA and collagen I expression. LWWL also suppressed hepatic stellate cell (HSC) activation by reducing the expression of the profibrogenic factors TGF-β1 and PDGF. The expression levels of TIMP1 and TIMP2, which regulate extracellular matrix (ECM) degradation, were decreased after CCl(4) injury in LWWL-treated rats. CONCLUSIONS: These data suggest that LWWL may serve as a promising therapeutic agent to reduce fibrogenesis. BioMed Central 2018-07-09 /pmc/articles/PMC6038198/ /pubmed/29986685 http://dx.doi.org/10.1186/s12906-018-2276-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Liu, Huimin
Zhang, Zhenfang
Hu, Huangwanyin
Zhang, Congen
Niu, Ming
Li, Ruishen
Wang, Jiabo
Bai, Zhaofang
Xiao, Xiaohe
Protective effects of Liuweiwuling tablets on carbon tetrachloride-induced hepatic fibrosis in rats
title Protective effects of Liuweiwuling tablets on carbon tetrachloride-induced hepatic fibrosis in rats
title_full Protective effects of Liuweiwuling tablets on carbon tetrachloride-induced hepatic fibrosis in rats
title_fullStr Protective effects of Liuweiwuling tablets on carbon tetrachloride-induced hepatic fibrosis in rats
title_full_unstemmed Protective effects of Liuweiwuling tablets on carbon tetrachloride-induced hepatic fibrosis in rats
title_short Protective effects of Liuweiwuling tablets on carbon tetrachloride-induced hepatic fibrosis in rats
title_sort protective effects of liuweiwuling tablets on carbon tetrachloride-induced hepatic fibrosis in rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038198/
https://www.ncbi.nlm.nih.gov/pubmed/29986685
http://dx.doi.org/10.1186/s12906-018-2276-8
work_keys_str_mv AT liuhuimin protectiveeffectsofliuweiwulingtabletsoncarbontetrachlorideinducedhepaticfibrosisinrats
AT zhangzhenfang protectiveeffectsofliuweiwulingtabletsoncarbontetrachlorideinducedhepaticfibrosisinrats
AT huhuangwanyin protectiveeffectsofliuweiwulingtabletsoncarbontetrachlorideinducedhepaticfibrosisinrats
AT zhangcongen protectiveeffectsofliuweiwulingtabletsoncarbontetrachlorideinducedhepaticfibrosisinrats
AT niuming protectiveeffectsofliuweiwulingtabletsoncarbontetrachlorideinducedhepaticfibrosisinrats
AT liruishen protectiveeffectsofliuweiwulingtabletsoncarbontetrachlorideinducedhepaticfibrosisinrats
AT wangjiabo protectiveeffectsofliuweiwulingtabletsoncarbontetrachlorideinducedhepaticfibrosisinrats
AT baizhaofang protectiveeffectsofliuweiwulingtabletsoncarbontetrachlorideinducedhepaticfibrosisinrats
AT xiaoxiaohe protectiveeffectsofliuweiwulingtabletsoncarbontetrachlorideinducedhepaticfibrosisinrats